Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - tacrolimus monohydrate, quantity: 5.1 mg (equivalent: tacrolimus, qty 5 mg) - capsule - excipient ingredients: dichloromethane; lactose; magnesium stearate; croscarmellose sodium; ethanol absolute; hypromellose; titanium dioxide; purified water; iron oxide red; gelatin; sodium lauryl sulfate - tacrolimus is indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - tacrolimus monohydrate, quantity: 5.1 mg (equivalent: tacrolimus, qty 5 mg) - capsule - excipient ingredients: lactose; dichloromethane; croscarmellose sodium; hypromellose; ethanol absolute; magnesium stearate; titanium dioxide; purified water; iron oxide red; gelatin; sodium lauryl sulfate - tacrolimus is indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - tacrolimus monohydrate, quantity: 1.02 mg (equivalent: tacrolimus, qty 1 mg) - capsule - excipient ingredients: hypromellose; magnesium stearate; dichloromethane; lactose; ethanol absolute; croscarmellose sodium; titanium dioxide; purified water; gelatin; sodium lauryl sulfate - tacrolimus is indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - tacrolimus, quantity: 0.5 mg - capsule, hard - excipient ingredients: lactose monohydrate; croscarmellose sodium; purified water; iron oxide yellow; magnesium stearate; hypromellose; titanium dioxide; gelatin; hyprolose; butan-1-ol; iron oxide red; industrial methylated spirit; simethicone; lecithin; ethanol; shellac; strong ammonia solution; sulfuric acid - prograf is indicated for use as an adjunct to liver, kidney, heart or lung allograft transplantation in adults and children.

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - tacrolimus, quantity: 5 mg - capsule, hard - excipient ingredients: lactose monohydrate; hypromellose; iron oxide red; gelatin; magnesium stearate; titanium dioxide; croscarmellose sodium; propylene glycol; butan-1-ol; isopropyl alcohol; ethanol; shellac; strong ammonia solution; sulfuric acid - prograf is indicated for use as an adjunct to liver, kidney, heart or lung allograft transplantation in adults and children.

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - tacrolimus, quantity: 1 mg - capsule, hard - excipient ingredients: titanium dioxide; croscarmellose sodium; hypromellose; magnesium stearate; lactose monohydrate; gelatin; purified water; hyprolose; butan-1-ol; iron oxide red; industrial methylated spirit; simethicone; lecithin; ethanol; shellac; strong ammonia solution; sulfuric acid - prograf is indicated for use as an adjunct to liver, kidney, heart or lung allograft transplantation in adults and children.

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - tacrolimus, quantity: 3 mg - capsule - excipient ingredients: hypromellose; ethylcellulose; lactose monohydrate; magnesium stearate; titanium dioxide; iron oxide yellow; iron oxide red; gelatin; sodium lauryl sulfate; hyprolose; butan-1-ol; purified water; industrial methylated spirit; simethicone; lecithin; ethanol; shellac; strong ammonia solution; sulfuric acid - indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - lenalidomide, quantity: 25 mg - capsule, hard - excipient ingredients: lactose; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm)- lenalidomide is indicated for treatment of multiple myeloma.,myelodysplastic syndromes (mds) - lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) - lenalidomide is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - lenalidomide, quantity: 15 mg - capsule, hard - excipient ingredients: lactose; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm)- lenalidomide is indicated for treatment of multiple myeloma.,myelodysplastic syndromes (mds) - lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) - lenalidomide is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - lenalidomide, quantity: 20 mg - capsule, hard - excipient ingredients: lactose; titanium dioxide; brilliant blue fcf; sunset yellow fcf; purified water; iron oxide yellow; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm)- lenalidomide is indicated for treatment of multiple myeloma.,myelodysplastic syndromes (mds) - lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) - lenalidomide is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.